The HCD Economics website provides access to the peer reviewed manuscripts published over recent years. In addition much of our research has been published at expert meetings in the form of abstracts, orals and posters.

However HCD Economics believes that peer review publication of full manuscripts, in respected journals, under the authorship of academic experts alongside the HCD research team, is the gold standard for presentation of results and contribution to the evidence base that can be used to achieve ‘what matters for patients’.

As we enter 2022, the HCD Economics team wanted to provide readers of the news page with an overview of the type of content that can be found in the section of this website that catalogue’s our full manuscript publications. (Publications: HCD Economics).

The emergence of Discrete Choice Experiments as a core expertise of the HCD Economics team is supported by the 2021 publication in Haemophilia (co-authors include Brian Mahony and other leaders from European and US Haemophilia societies) which compares patient preferences for treatment in haemophilia, as such, this paper is an early contribution to the patient and public engagement debate for the introduction and access to gene therapy in haemophilia.

HCD Economics proprietary study design for assessing burden of illness, collectively described as the BOI studies, always includes a publication authored by the expert review group that is established to supervise the design and conduct of each BOI study. These manuscripts report the first top line results for the CHESS (multiple studies), BRASS, LUCID, PICTURE and GAIN studies (Haemophilia, Rheumatoid Arthritis, Ulcerative Colitis, Progressive Familial Intrahepatic Cholestasis and Non-Alcoholic Steatohepatitis disease respectively)

The BOI studies also feature in a number of publications that report health economic analysis undertaken to address specific questions, drawing upon the database for these studies. Research questions include the economic assessment of joint damage, burden in the US healthcare system, short term outcomes and associated costs, long term outcomes within disease and the economic impact of new healthcare interventions and the implications of a disease on pain and as measured by the economics of the impact on work, productivity and early retirement.

Techniques reported in manuscripts include modelling (including use of generalized linear models, univariate and multivariate analysis, logistic regression). Other evidence generation methods include conducting a systematic literature review, a comprehensive treatment review that draws upon all sources of data from treatment observation to animal studies that offer insight to drug effect in the patient. Expert elicitation exercises and patient assessment of outcome are also among the studies in the papers recently published.

HCD Economics authors have also been published in the area of policy development. These include terminology optimisation and defining best methods for deciding upon resource allocation by those responsible for healthcare budget decision making.

Our projects can be narrowed to identifying the optimal technique to address a specific health economic questions, plus the team will evolve new concepts to support increased understanding of what matters to patients, for example the process and outcome of the HCD Economics concept of the disability paradox is available in a series of papers, as is the work done in the understanding the implication of target joints in haemophilia.

We are looking forward to further work being published in 2022. If readers would like to be directed to a link for a publication of interest, please contact Alison Rose –